Product Information
DEFERASIROX 180 MG TABLET is a generic product labeled by NorthStar Rx LLC, priced at $0.8750 per EA under NDC 72603023201. Its NADAC has been published 59 times since Aug 20, 2025.
FDA first approved this application on Oct 16, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
180 mg/1
Manufacturer
NorthStar Rx LLCNDC
72603023201
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
10/22/2025
Active Ingredients
DEFERASIROXApproval Type
Generic (ANDA)
FDA Application
ANDA214474FDA Approved
10/16/2023
TE Code
AB
On Market Since
10/16/2023
Pharmacological Classes
Price Statistics
The NADAC for DEFERASIROX 180 MG TABLET has been published 59 times since Aug 20, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8750 per EA |
|---|---|
| All-time high | $0.8750 (Sep 30, 2026) |
| All-time low | $0.8750 (Aug 20, 2025) |
| 52-week high | $0.8750 |
| 52-week low | $0.8750 |
| Median price | $0.8750 |
| Average price | $0.8750 |
| Largest weekly change | 0.0% (Aug 27, 2025) |
| Weeks tracked | 59 |
| Tracking since | Aug 20, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
NorthStar Rx LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
DEFERASIROX market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Iron Chelator class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DEFERASIROX 180 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DEFERASIROX 180 MG TABLET, manufactured by NorthStar Rx LLC, is $0.8750 per EA (NDC 72603023201), effective Sep 30, 2026.
How has the price of DEFERASIROX 180 MG TABLET changed over time?
Over the history we have for it, the NADAC for DEFERASIROX 180 MG TABLET has held within roughly two percent of its current level. It has been tracked across 59 weekly CMS publications since Aug 20, 2025.
What are the highest and lowest recorded NADAC prices for DEFERASIROX 180 MG TABLET?
Since Aug 20, 2025, the NADAC for DEFERASIROX 180 MG TABLET has ranged from a low of $0.8750 (Aug 20, 2025) to a high of $0.8750 (Sep 30, 2026), with a median of $0.8750 per EA.
Are there cheaper alternatives to DEFERASIROX 180 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as DEFERASIROX 180 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures DEFERASIROX 180 MG TABLET?
DEFERASIROX 180 MG TABLET (NDC 72603023201) is labeled by NorthStar Rx LLC, and CMS classifies it as a generic product.